(Q37671987)

21 August 2017

0 references

1 reference

title

Induction and maintenance therapy for lupus nephritis: a systematic review and meta-analysis (English)

1 reference

21 August 2017

0 references

1 reference

1 reference

Y H Lee

1

1 reference

21 August 2017

J-H Woo

2

1 reference

21 August 2017

S J Choi

3

1 reference

21 August 2017

J D Ji

4

1 reference

21 August 2017

G G Song

5

1 reference

21 August 2017

language of work or name

1 reference

11 January 2010

1 reference

21 August 2017

1 reference

21 August 2017

volume

19

1 reference

21 August 2017

issue

6

1 reference

21 August 2017

page(s)

703-710

1 reference

Unraveling the genetics of systemic lupus erythematosus

21 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F0961203309357763

Update on the treatment of lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203309357763

Lupus in the 1980s: III. Influence of clinical variables, biopsy, and treatment on the outcome in 150 patients with lupus nephritis seen at a single center

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203309357763

Cyclophosphamide: new approaches for systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203309357763

Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203309357763

A comparative study of two intensified pulse cyclophosphamide remission-inducing regimens for diffuse proliferative lupus nephritis: an Egyptian experience.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203309357763

Randomized controlled trial of pulse intravenous cyclophosphamide versus mycophenolate mofetil in the induction therapy of proliferative lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203309357763

Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203309357763

Mycophenolate mofetil in lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203309357763

Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203309357763

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203309357763

Bias in meta-analysis detected by a simple, graphical test

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203309357763

Quantifying heterogeneity in a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203309357763

Mycophenolate mofetil for induction therapy of lupus nephritis: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203309357763

Systematic review and meta-analysis of randomised trials and cohort studies of mycophenolate mofetil in lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203309357763

Randomized, controlled trial of prednisone, cyclophosphamide, and cyclosporine in lupus membranous nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203309357763

Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from long-term followup of patients in the Euro-Lupus Nephritis Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203309357763

Mycophenolate mofetil is as efficacious as, but safer than, cyclophosphamide in the treatment of proliferative lupus nephritis: a meta-analysis and meta-regression

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203309357763

Treatment options for proliferative lupus nephritis: an update of clinical trial evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203309357763

Mycophenolate mofetil in induction and maintenance therapy of severe lupus nephritis: a meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203309357763

Mycophenolate mofetil versus azathioprine in the maintenance therapy of lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203309357763

Sequential therapies for proliferative lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203309357763

EULAR randomised controlled trial of pulse cyclophosphamide and methylprednisolone versus continuous cyclophosphamide and prednisolone followed by azathioprine and prednisolone in lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203309357763

Treatment of diffuse proliferative lupus glomerulonephritis: a comparison of two cyclophosphamide-containing regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203309357763

21 January 2018

Identifiers

DOI

10.1177/0961203309357763

1 reference

21 August 2017

1 reference